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ABSTRACT 
Epidemiological studies have identified that type 2 diabetes mellitus (DM2) is 
a significant risk factor for carcinogenesis and cancer death, including breast cancer. 
Our previous finding in patients showed that anti-insulin resistance treatments are 
associated with improved HER2
+
 breast cancer survival of diabetic women. However, 
there were no transgenic mouse models to study the correlation and explain the 
detailed mechanism. We generated a mouse model of HER2
+
 breast cancer with DM2 
by crossing leptin receptor point mutation (Lepr 
db/+
) and MMTV-ErbB2 (neu) mice. 
The MMTV-ErbB2/Lepr 
db/db
 mice had a poor survival rate compared with MMTV-
ErbB2/Lepr 
+/+ 
mice, and the log rank test of the Kaplan-Meier analysis showed that 
they were significantly different (P = 0.0004). In addition, we evaluated the impact of 
different anti-diabetic medications on cancer-specific survival. MMTV-ErbB2/Lepr 
db/db
 mice administrated with metformin or rosiglitazone showed improved overall 
survival, cumulative tumor incidence, and reduced tumor progression. Anti-insulin 
resistance treatments can also reverse the Warburg effect by reducing lactate/pyruvate 
ratio through 
13
C-pyruvate imaging. Cell lines isolated from MMTV-ErbB2/Lepr 
db/db
 
mice also showed reduced levels of both oxygen consumption and lactate production 
upon metformin treatment. Metformin treatment not only inhibited proliferation and 
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induced apoptosis in Human HER2
+
 breast cancer cell lines, but also repressed c-
MYC mRNA expression, increased proteasome-dependent degradation, and reduced 
the downstream key glycolysis enzyme PKM2. Moreover, anti-insulin resistance 
treatments dramatically change the microenvironment by reducing serum insulin 
levels and this systematic effect attenuated the mTOR/AKT signaling pathway in 
tumor samples from MMTV-ErbB2/Lepr 
db/db
 mice. Anti-insulin resistance treatments 
also affected adipokine expression profiles and may reveal potential targets for 
further research. In conclusion, our results indicate the therapeutic effect of anti-
insulin resistance treatments on breast cancer metabolism and this animal model also 
shed the light on the clinical implications of anti-insulin resistance treatments on 
HER2
+
 breast cancer patients accompanied with the DM2 condition. 
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CHAPTER 1. INTRODUCTION 
 
1.1 General background of diabetes mellitus 
Diabetes mellitus, or simply diabetes, is a complex metabolic disease 
characterized by chronic hyperglycemia and becoming one of the most 
important health issues in the United States. According to the Centers for 
Disease Control and Prevention (CDC), diabetes affects 25.8 million 
Americans which are 8.3% of the U.S. population in 2011. Based on the 
percentage of prediabetes patients (35% of U.S. adults aged 20 years old or 
older and 50% of adults aged 65 years or older) in 2005-2008, the estimated 
number of pre-diabetic American adults ages 20 years or older is about 79 
million. It is predicted that one of three man and nearly 2 of 5 women who 
born in the U.S. after 200 will have lifetime risk of developing diabetes 
(Centers for Disease Control and Prevention. National Center for Chronic 
Disease Prevention and Health Promotion. Diabetes at A Glance. Atlanta, 
2011; Narayan et al., 2003). The chronic hyperglycemia increases the risk of 
long-term complications of vascular diseases including kidney failure, 
nontraumatic lower-limb amputations, blindness, hypertension, heart disease, 
stroke, and nervous system diseases in the United States. 
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1.1.a Categorization of diabetes mellitus 
The high levels of blood glucose of diabetes are results from defects in insulin 
insulin production, insulin action, or both. Diabetes can be categorized into four 
four major types based on American Diabetes Association (2011): 
 
Type I diabetes: This type of diabetes is primarily caused by autoimmune 
destruction of β-cells in the pancreas islet. The insulin production from the β-cells in 
the pancreas is not sufficient for glucose storage, therefore hyperglycemia. The cause 
of this diabetes is partly genetic predispositions, and is also related to environment. 
At the end stage, there is little or no insulin secretion from the β-cells and insulin is 
required for patient survival. This type of patients is also at higher risk to develop 
other autoimmune diseases. 
 
Type II diabetes: Among all patients with diabetes, more than 90% diabetic 
patients are having diabetes mellitus type 2 (DM2), which is characterized by insulin 
resistance, and the majority of the DM2 patients are overweight and a sedentary life 
style (Giovannucci et al., 2010). This form of diabetes is previously defined as 
insulin-independent diabetes with an insulin resistance phenotype. The cause of this 
type of diabetes is more related with life style and Western diet.  
 
Other specific types of diabetes: There are also other types of diabetes that 
were caused by other reasons, e.g. genetic mutations in β-cell function, insulin action, 
cystic fibrosis, and drug/chemical-induced diabetes as shown in Table 1. 
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Gestational diabetes mellitus: This form of diabetes is carbohydrate 
intolerance resulting in hyperglycemia during pregnancy. Women who 
develop gestational diabetes will have high risk to develop DM2. 
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Table 1—Etiologic classification of diabetes mellitus 
(adapted from American Diabetes Association, Diabetes Care 2011, 34(S1): S62-S69) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune mediated 
B. Idiopathic 
 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with insulin resistance) 
 
III. Other specific types 
A. Genetic defects of β-cell function 
1. Chromosome 12, HNF-1α (MODY3) 
2. Chromosome 7, glucokinase (MODY2) 
3. Chromosome 20, HNF-4α (MODY1) 
4. Chromosome 13, insulin promoter factor-1 
 (IPF-1; MODY4) 
5. Chromosome 17, HNF-1β (MODY5) 
6. Chromosome 2, NeuroD1 (MODY6) 
7. Mitochondrial DNA 
 
B. Genetic defects in insulin action 
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
 
D. Endocrinopathies 
1. Acromegaly 
2. Cushing’s syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
 
 
IV. Gestational diabetes mellitus 
 
Patients with any form of diabetes may require insulin treatment at some stage of their 
disease. Such use of insulin does not, of itself, classify the patient. 
E. Drug or chemical induced 
1. N-3-pyridylmethyl-N’-p-
nitrophenylurea 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Diazoxide 
6. β-adrenergic agonists 
7. Thiazides 
8. Phenytoin 
9. γ-Interferon 
 
F. Infections 
1. Congenital rubella 
2. Cytomegalovirus 
 
G. Uncommon forms of immune-
mediated diabetes 
1. “Stiff-man” syndrome 
2. Anti-insulin receptor antibodies 
 
H. Other genetic syndromes 
sometimes associated with diabetes 
1. Down syndrome 
2. Klinefelter syndrome 
3. Turner syndrome 
4. Wolfram syndrome 
5. Friedreich ataxia 
6. Huntington chorea 
7. Laurence-Moon-Biedl 
syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
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1.2 General background of breast cancer 
Although breast cancer mortality is decreasing due to increased 
awareness, improved detection/screening methods, and novel treatments, it is 
remaining the most frequent diagnosed cancer and the second leading cause of 
cancer death in women. During 2014, there are estimated 232,670 new cases 
of invasive breast cancer and an estimated 40,000 of breast cancer death for 
women in the United States. The lifetime risk for women to develop breast 
cancer is about one in eight (American Cancer Society, 2014). 
 
Breast cancer is now considered a heterogeneous group of diseases 
that have different molecular subtypes and responses to the treatments. 
Therefore, they need to be well categorized in order to achieve effective 
treatments. By taking advantage of DNA microarray technology, we could 
classify breast cancer gene expression profiles and cluster them into five main 
molecular subtypes as shown in Figure 1. (Herschkowitz et al., 2007; Perou et 
al., 2000; Prat and Perou, 2009, 2011; Vargo-Gogola and Rosen, 2007). The 
five molecular subtypes are: Luminal A, Luminal B, HER2, basal-like and 
claudin-low breast cancer. These subtypes can also be identified by using cell 
surface receptors as biological markers including estrogen receptors (ER+/ER-
), progesterone receptors (PR+/PR-), and human epidermal growth factor 
receptor 2 (HER2+/HER2-) (Reis-Filho and Pusztai, 2011). By categorizing 
different types of breast cancer, we are able to predict the prognosis and select  
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Figure 1. The five major subtypes of breast cancer and the link to normal 
human mammary epithelial hierarchy 
Breast cancer can be categorized into five major subtypes by clustering their 
molecular expression patterns of normal breast tissue and breast cancer. These cancer 
cells may differentiate at certain stage and become one type of breast cancer. The 
expression pattern of Luminal, Mesenchymal, and Basal-like is more like a 
continuous spectrum instead of discrete discontinuous entities. Mammary stem cell 
(MaSC) has similar expression pattern compared to Claudin-low subtype of breast 
cancer. (Adapted by permission from Macmillan Publisher LtD: Nature Medicine, 
Part et al., Nat Med. 2009, 15(8): 842-4, Copyright 2009).  
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suitable treatments for breast cancer patients (Goldhirsch et al., 2011) as shown in 
Figure 2. 
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Figure 2. Patient relapse survival and overall survival on different breast cancer 
subtypes 
Kaplan-Meier survival curves were plotted by using UNC337 data set. (Adapted by 
permission from Elsevier: Molecular Oncology, 5(1), Prat and Perou, Deconstructing 
the molecular portraits of breast cancer, 5-23, Copyright Elsevier (2011). 
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Luminal A breast cancer is the most common subtype representing 
about 40% in the breast cancer population (Perou and Borresen-Dale, 2011) 
and the receptor status of these tumors is ER+ and/or PR+ and HER2-. 
Because of the expression of ER, hormonal therapy strategies such as 
tomaxifen and aromatase inhibitors could be considered as treatment options 
for patients. In clinic, luminal A breast cancer shows low proliferation, low 
grade, less aggressive phenotype, and has better outcome in patient survival. 
 
Luminal B breast cancer is ER+ and /or PR+. The HER2 status can 
be either HER2+ or HER2- with high Ki67 staining. The histological grade 
lymph node-positive rate is higher comparing to Luminal A (Voduc et al., 
2010). The prognosis is not so good comparing with Luminal A breast cancer, 
but can use hormonal therapies as treatment options. 
 
HER2
+
 breast cancer accounts for 20-25% of breast cancer cases and 
is associated with poor prognosis with early and frequent recurrence (Piccart-
Gebhart et al., 2005; Sorlie et al., 2003). Patients in this group have high level 
of HER2 expression with high metastasis rate and aggressive phenotype. 
Trastuzumab (Herceptin) treatment significantly improves patient survival 
(Ross et al., 2003). 
 
Basal-like breast cancer can be clinically referred to triple negative 
breast cancer based on the receptor status (ER-, PR-, and HER2-) although the 
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molecular expression profiles can be not exactly the same. The tumors usually have 
high expression in basal epithelial markers (i.e. cytokeratins) and growth factor 
receptors (i.e. EGFR) (Sorlie et al., 2003; Sotiriou et al., 2003). 
 
Claudin-low breast cancer is recently identified by the low expression of 
tight junction and cell adhesion proteins (Claudins 3, 4, 7, Occludin, and E-cadherin) 
(Herschkowitz et al., 2007) with ER-, PR- HER2- phenotype. The molecular 
expression pattern is similar to the stem cell stage compared to the normal mammary 
development (Prat et al., 2010). The stem-cell property might contribute the 
recurrence and poor prognosis in patients (Creighton et al., 2009). 
 
There is also a group of breast cancer called normal-like breast cancer and the 
gene expression pattern is very close to normal breast tissue. In fact, the normal-like 
breast cancer samples for microarray studies have always contained normal breast 
tissue which might explain why this group was clustered with normal breast tissue in 
the gene expression profiling analysis (Prat and Perou, 2011). It needs to be further 
confirmed with large scale of data. In clinic, normal-like tumors are usually small and 
the patients usually have good prognosis (Carey et al., 2006; Fan et al., 2006).  
 
In conclusion, the transcriptomic analyses allow us to understand the origin of 
breast cancer and reveal potential therapeutic targets for different types of breast 
cancer. Although the target therapies had been established to different types of breast 
cancer, many cancer patients eventually develop resistance for their treatments. On 
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the other hand, patients who were diagnosed with breast cancer may also 
under multiple chronic conditions, including diabetes. Better understanding of 
intervention treatments to manage breast cancer and other complications will 
allow us to develop new therapeutic strategies to treat breast cancer. 
 
1.3 Diabetes treatments, insulin levels, and anti-cancer effects 
Although diabetes is a serious disease, it can be managed with proper 
treatments. In the clinic, one of the primary goals to manage diabetes is to 
reduce the blood glucose level in patients. Therefore, doctors may prescribe 
insulin or modified insulins to diabetic patients regardless of the serum level 
of insulin in the patients. More insulin will increase the uptake of glucose and 
reduce the level of glucose in the blood in diabetic patients. There are other 
treatment options that involved in increase insulin levels. While sylfonylureas 
and glinides stimulate insulin release from the β-cells of the pancreas, 
glucagon-like peptide-1 (GLP-1) receptor agonists not only stimulate insulin 
secretion from the β–cells of the pancreas, but also inhibit glucagon release 
from the α-cells. Besides that, DPP-4 inhibitors increase GLP-1 and glucose-
dependent insulinotropic polypeptide (GIP) by inhibiting the enzyme that 
degrades incretin hormones. However, the increased circulating levels of 
insulin is linked to a higher risk of cancer (Bowker et al., 2006; Butler, 2009; 
Colhoun, 2009; Hemkens et al., 2009; Monami et al., 2009). 
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There are also treatments that do not directly regulate insulin levels, such as 
α–glucosidase inhibitors and amylin agonists. While α–glucosidase inhibitors block 
carbohydrate digestion, amylin agonists slow down gastric emptying and inhibit 
glucogon production. Surprisingly, biguanides (e.g., metformin) and 
thiazolidinediones (e.g., rosiglitazone) are two common orally administered 
treatments for DM2 and have showed anti-tumor effect for multiple cancer types (Ben 
Sahra et al., 2008; Buzzai et al., 2007; Giovannucci et al., 2010; Girnun et al., 2007; 
Hirsch et al., 2013; Monami et al., 2008), including breast cancer (Zhu et al., 2011; 
Zhuang and Miskimins, 2008). 
 
1.3.a Metformin 
Metformin is recommended as a first line treatment for DM2 with high 
tolerance and low side effect. Although the usage of metformin was linked to lactic 
acidosis (Wiholm and Myrhed, 1993), a meta-analysis study had showed that the 
incidence of lactic acidosis in the metformin and non-metformin group was 8.1 and 
9.9 cases per 100,000 patient-years, respectively (Salpeter et al., 2003). Another new 
study done by Bristol-Myers Squibb Company indicated that there is no lactic 
acidosis in 7,227 patients who received metformin treatment (Cryer et al., 2005).  
Even though the detail mechanism of metformin action is only partially 
understood, the major function of metformin is to lower glucose levels and to 
improve insulin sensitivity. It is believed that the high levels of organic cation 
transporter 1 (OCT1) in the liver mediate hepatic metformin uptake (Shu et al., 2007). 
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Metformin improves insulin receptor sensitivity through upregulation of 
insulin-receptor-substrate-2 (IRS-2) in the liver. It also increases translocation 
of glucose transporter (GLUT)-1 (Gunton et al., 2003). At the same time, 
metformin inhibits hepatic gluconeogenesis (Shaw et al., 2005). It is also 
reported that metformin treatment increases glucose uptake in the skeletal 
muscle (McIntyre et al., 1991). 
 
Metformin is also a well-known mitochondrial complex I inhibitor 
(Owen et al., 2000). Once the mitochondrial electron transport chain is 
inhibited, adenosine triphosphate (ATP) production in the cell is decreased 
and adenosine monophosphate (AMP)/ATP ratio is increased. The 
upregulated AMP may lead to the inhibition of glucagon-induced cyclic 
adenosine monophosphate (cAMP) synthesis (Miller et al., 2013) or AMPK 
activation (Fryer et al., 2002). Although it is believed that metformin activated 
AMPK and mediated glucose homeostasis (Zhou et al., 2001) through Liver 
Kinase B1 (LKB1) (Shaw et al., 2005), a recent study indicated that 
metformin inhibits hepatic gluconeogenesis through a LKB1/AMPK 
independent pathway (Foretz et al., 2010). 
 
1.3.b Rosiglitazone 
Rosiglitazone is one of the thiazolidinediones (TZDs) available for 
diabetic patients to control their blood glucose. TZDs are agonists of 
peroxisome proliferator-activated receptor γ (PPARγ) (Lehmann et al., 1995). 
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By administrating rosiglitazone to the patients, PPARγ receptors in the nucleus are 
activated in a ligand-receptor dependent fashion and increase the sensitivity of insulin 
by turning on downstream gene expression that involved in glucose uptake (Yki-
Jarvinen, 2004). 
 
Rosiglitazone has been associated with an increased risk of heart attack, stroke 
and fluid retention (Home et al., 2007; Nissen and Wolski, 2007). The U.S. Food and 
Drug Administration (FDA) announced to restrict the usage on patients in 2010 
(Graham and Gelperin, 2010; Graham et al., 2010). However, recent results from the 
re-adjudication of Rosiglitazone Evaluated for Cardiovascular Outcomes and 
Regulation of Glycemia in Diabetes (RECORD) clinical trial showed no elevated risk 
of heart attack or death in patients treated with rosiglitazone comparing with other 
standard treatments (Mitka, 2013). Therefore, the restriction has been removed by the 
FDA on November 25
th
, 2013. 
 
Rosiglitazone treatment showed decreased cancer risk in patients (Chang et al., 
2012; Monami et al., 2014; Monami et al., 2008). From previous studies, 
rosiglitazone treatment induces apoptosis (Ohta et al., 2001; Zou et al., 2007), blocks 
cell cycle (Han et al., 2004), promotes differentiation (Bren-Mattison et al., 2005), 
inhibits angiogenesis (Keshamouni et al., 2005) and suppresses immune response 
(Bren-Mattison et al., 2008). PPARγ is also one of the upstream transcriptional 
regulators for PTEN (Cao et al., 2007; Lee et al., 2006; Patel et al., 2001). Increased 
PTEN inhibits mTOR/AKT signaling pathway which is largely involved in 
 
 
15 
 
tumorigenesis (Maehama and Dixon, 1998). Rosiglitazone treatment also 
induces AMPK activation (Fryer et al., 2002; Han and Roman, 2006) and 
inhibits mitochondrial oxidation independent of PPARγ signaling pathway 
(Brunmair et al., 2001). 
 
1.3.c Anti-insulin resistance treatments and HER2
+
 cancer 
Our recent study suggested that these pharmacologic treatments for 
DM2 may reduce risk, morbidity, and mortality of breast cancer with 
overexpression or amplification of human epidermal growth factor receptor 2 
(HER2) (He et al., 2012). Several research groups have investigated the 
anticancer effect of the anti-insulin resistance treatments in HER2
+
 breast 
cancer in vitro (Feng et al., 2011; Zhuang and Miskimins, 2008) and in vivo 
(Anisimov et al., 2005a; Anisimov et al., 2005b).  However, the in vitro 
experiments performed in cell lines could not reflect the interaction between 
cancer cells and stromal cells, and unfortunately, the in vivo xenograft 
experiments were performed in nude mice or severe combined 
immunodeficiency (SCID) mice that lacked an intact immune system, which 
is essential for cancer progression. Moreover, neither high-fat diet-induced 
nor drug-induced diabetes models can mimic diabetes development in patients. 
Similarly, a transgenic diabetic model without obese conditions (Fierz et al., 
2013) also could not reflect the fact that 80% of DM2 patients are overweight 
or obese. Therefore, a transgenic animal model with DM2, obesity, and an 
intact immune system to evaluate the correlation between breast cancer and 
 
 
16 
 
DM2 is necessary to answer the underlying questions about how anti-insulin 
resistance treatments reduce cancer progression. 
 
1.4 Gap in knowledge 
Clinical studies showed that diabetes is a risk factor of breast cancer. However, 
there is no animal model to address the impact of DM2 on HER2+ breast cancer. 
Previous study showed that mice with homozygous leptin receptor point mutation 
(Lepr
db/db
) did not develop oncogene-induced mammary tumors in a C57BL/6J 
background (Cleary et al., 2004). However, the C57BL/6J (B6) genetic background is 
resistant to carcinogenesis (DiGiovanni et al., 1993; Drinkwater and Ginsler, 1986; 
Fischer et al., 1989; Rowse et al., 1998).  
 
To clarify this question, we decided to cross MMTV-ErbB2 mice with 
Lepr
db/+
 mice to generate a diabetic HER2
+
 breast cancer mouse model in a Friend 
leukemia virus B (FVB) genetic background. This is the first transgenic animal in a 
DM2 setting with spontaneous HER2
+
 tumor development and we would like to 
know whether DM2 promotes breast cancer progression. Furthermore, we would like 
to test that this aggressiveness caused by DM2 can be attenuated by anti-insulin 
resistance treatments in a clinical relevant concentration. The data we collected are 
described in the following chapters. These results may bring attention to doctors who 
treat HER2
+
 breast cancer patients with diabetes about their choice of anti-diabetic 
medications. 
  
 
 
17 
 
CHAPTER 2. MATERIAL and METHODS 
 
2.1 Mouse Tumor Model 
MMTV-ErbB2 mice (strain name: FVB-Tg (MMTV-Erbb2) 
NK1Mul/J; stock number: 005038) and Lepr
db/db
 mice (strain name: B6.BKS 
(D)-Lepr
db
/J; stock number: 000697) were purchased from The Jackson 
Laboratory (Maine, USA). MMTV-ErbB2/Lepr
db/db
 double-transgenic mice 
were generated by crossing male MMTV-ErbB2 mice with female Lepr
db/+
 
mice in an FVB genetic background (Figure 3). This is necessary because 
MMTV-ErbB2 female mice, although fertile, are unable to lactate, and the 
Lepr
db/db
 mice were infertile. This breeding strategy resulted in the production 
of all three Lepr genotypes. The offspring were maintained with their mothers 
until age 21 days and then subjected to genotyping. All mouse studies were 
carried out under a protocol approved by The University of Texas MD 
Anderson Cancer Center Institutional Animal Care and Use Committee. 
 
2.2 Genotyping, Weight Measurement, Oral Glucose Tolerance Tests and Insulin 
Tolerance Tests 
Mouse tails were snipped at weaning, and DNA was extracted from 
the tail for genotyping following a standard protocol provided by The Jackson 
Laboratory. The mice were weighted twice each week. The weight data were 
separated and plotted based on different genotypes. Oral glucose tolerance 
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tests (OGTTs) and insulin tolerance tests (ITTs) were performed as previously 
described (Dezaki et al., 2004). 
 
 
 
 
 
 
 
 
 
Figure 3. Scheme of mouse breading 
MMTV-ErbB2 mice were crossed with Lepr
db/+
 mice in FVB background. 
Genotyping were performed, and mice carring MMTV-ErbB2 gene were collected for 
further study. 
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Briefly, for OGTTs, animals were fasting overnight and 1 g/kg glucose 
was given to the mice via oral gavage followed by blood sampling from the 
tail vein for glucose measurement. For ITTs, animals were fasting for 6 hours. 
Insulin (1 U/kg) was intraperitoneally injected, and blood was collected from 
the tail vein for glucose measurement. Statistical analysis was done with 
GraphPad Prism for Windows. 
 
2.3 Mammary Gland Whole-Mount Staining 
Mammary gland whole-mount staining was performed following 
standard procedures. Briefly, mammary glands were fixed on glass slides with 
Carnoy’s solution (glacial acetic: choloroform: ethanol, 1: 3: 6) overnight at 
room temperature (RT). The glands were rehydrated prior to overnight 
staining in aluminum carmine (1 g carmine, 2.5 g aluminum potassium sulfate 
boiled for 20 minutes in distilled water, filtered, and brought to a final volume 
of 500 mL). The glands were then stored in 70% ethanol at 4ºC overnight. 
Photographs were taken under a 4x power objective lens using a digital 
camera mounted on a Leica MZ125 microscope (Leica Instruments, Wetzlar, 
Germany). The tumor area was quantified using Image-Pro Plus software 
(MediaCybernetics, Rockville, MD, USA). Statistical analysis was done with 
GraphPad Prism for Windows. 
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2.4 Anti-diabetic Drug Treatments 
For in vivo experiments, MMTV-ErbB2/Lepr
db/db
 mice were treated with 
metformin or rosiglitazone starting at 8 weeks old. Metformin (Enzo Life Sciences, 
cat# 270-432-G005) was dissolved directly in distilled water (0.5 g/kg/day). 
Rosiglitazone (Cayman Chemical, cat# 71740) was dissolved in dimethyl sulfoxide as 
stock solution at 100 mM and added to distilled water (1.5 mg/kg/day). The drug 
treatment concentrations were within the physiologically relevant levels for diabetic 
patients. 
 
For in vitro studies, metformin was directly dissolved in cell culture medium 
at desired concentrations, and 100 mM stock rosiglitazone was added into cell culture 
medium at desired concentrations. 
 
2.5 Survival Analysis 
Paired mice were randomly assigned to different cohorts for survival analysis. 
To assess the impact of diabetes on survival, we compared the survival time of 
MMTV-ErbB2/Lepr
db/db
 mice (n=16) with that of MMTV-ErbB2/Lepr
db/db
 mice 
(n=12). To assess the impact of anti-insulin resistance treatments on survival, we 
compared MMTV-ErbB2/Lepr
db/db
 mice treated with metformin (n=14) or 
rosiglitazone (n=14) with MMTV-ErbB2/Lepr
db/db
 mice without treatment (n=12). All 
mice were monitored weekly for tumor growth and were euthanized according to 
institutional protocol when tumor size reached the standard for euthanasia. Statistical 
analysis was done with GraphPad Prism for Windows. 
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2.6 Histology Staining and Mitosis Count 
After the mice were euthanized, tumor samples were removed, washed 
in phosphate buffered saline, weighted, and fixed in 10% modified formalin. 
After incubation in 70% ethanol overnight, the samples were embedded in 
paraffin. Paraffin-embedded sections were stained with hematoxylin and eosin 
according to standard procedures, and mitotic cells were counted under 40x 
high-power fields by a pathologist. 
 
2.7 Cell Lines and Cell Culture 
Mouse cell lines were isolated from MMTV-ErbB2/Lepr
db/db
 mice and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with high 
glucose (HyClone, ref# SH30243.01) with 20% fetal bovine serum (FBS). 
BT-474 and MDA-MB-361 cells were gifts from Dr. Mien-Chie Hung. 
Briefly, cells were maintained in DMEM/high glucose supplemented with 
10% FBS and cultured at 37 °C in 5 % CO2 conditions. 
 
2.8 Magnetic Resonance Spectroscopic Imaging 
To determine the pyruvate/lactate conversion in mice, we collaborated 
with Dr. James A. Bankson in the Department of Imaging Physics at The 
University of Texas MD Anderson Cancer Center, and magnetic resonance 
spectroscopic imaging (MRSI) (Day et al., 2007; Golman et al., 2006) was 
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performed as described below. All experiments were performed on the same mice 
before and after anti-insulin resistance treatments were administered. 
 
2.8.1 
13
C Polarization Process 
Samples composed of 26-mg neat [1-
13
C] pyruvic acid containing 15 mM of 
the trityl radical OX063 (GE Healthcare, Waukesha, WI) and 1.5 mM Prohance 
(Bracco Diagnostics) were polarized with  dynamic nuclear polarization (DNP) at 1.4 
K using a Hypersense (Oxford Instruments, Abingdon, UK) polarizer.  The samples 
were inserted into a 3.35-Tesla vertical bore magnet and irradiated for more than 45 
minutes with 94.15 GHz microwave radiation.  The frozen samples were then rapidly 
dissolved at 180°C in a 4 mL buffer containing 40 mM TRIS, 80 mM NaOH, and 50 
mM NaCl to a final isotonic and neutral solution containing 80 mH hyperpolarized 
[1-
13
C] pyruvate. 
 
2.8.2 MRI Imaging Acquisition 
All experiments were performed on a 7 T Biospec small animal MRI scanner 
(USR70/30, Bruker Biospin MRI, MA) equipped with BGA12 gradients (120 mm 
inner diameter, Gmax = 400 mT/m). A dual-tuned 
1
H/
13
C birdcage coil with 72-mm 
inner diameter (1P T10334, Bruker Biospin MRI, Inc., Ettlingen, Germany) was used 
for acquiring 
1
H reference images and performing hyperpolarized 
13
C dynamic 
spectroscopy. Axial and coronal slices were prescribed to contain tumors in various 
locations of mammary fat pads. A slice-selective pulse acquire 
13
C sequence (TR/TE 
= 2000/2.4 ms, 2048 readout points, 4.96 kHz BW, 10° flip angle, 96 repetitions) was 
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initiated prior to ~10 s the injection of 200 µL of the hyperpolarized [1-
13
C] 
pyruvate solution was performed via tail vein. 
 
2.8.3 Data Processing 
All data were processed and analyzed using custom MATLAB (The 
MathWorks, Inc., Natick, MA) scripts developed in our laboratory. For 
hyperpolarized 
13
C experiments, data were apodized by a 15 Hz exponential 
window and processed by fast Fourier transform. The signal intensity from 
13
C metabolites was calculated based on the spectral area over the full width 
half max, the sum of spectra over all repetitions, and the total lactate signal 
normalized by the sum of total pyruvate and lactate signals. 
 
2.9 Measurement of Oxygen Consumption Rate and Extracellular Acidification 
Rate in Mouse mammary tumor cells from MMTV-ErbB2/Lepr
db/db
 mice 
To further determine the impact of anti-insulin resistance treatment on 
cancer metabolism in vitro, we isolated the cancer cells from tumors of the 
MMTV-ErbB2/Lepr
db/db
 mice without any treatment and cultured the cells in a 
24-well microplate (Seahorse Bioscience). The oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) were measured via a 
Seahorse XF24 instrument (Seahorse Bioscience) according to the 
manufacturer’s instructions. Briefly, mouse tumor cells were pretreated with 
low concentration of metformin (300 µM) and then seeded in an XF24 
microplate 16 hours before the experiment. Just before the Seahorse XF assay, 
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the culture medium was replaced with assay medium (low-buffered DMEM 
containing 25 mM D-glucose, 1 mM of sodium pyruvate, and 1 mM of L-glutamine) 
and incubated for 1 hour at 37 ºC. After a baseline measurement of OCR and ECAR, 
75 μl of mitochondrial respiratory chain inhibitors was sequentially injected into each 
well to reach the final working 1X concentrations. After 5 minutes of mixing to 
equally expose the cancer cells to the chemical inhibitors, OCR and ECAR were 
measured. OCR was reported in pmol/minute/mg, and ECAR was reported in 
mpH/minute/mg. Results were analyzed using Seahorse XF software. Statistical 
analysis was done with GraphPad Prism for Windows. 
 
2.10 Proliferation assay 
Human HER2
+
 breast cancer  cell lines (BT-474 and MDA-MB-361) were 
split in low density in 100 mm
2
 dishes and cultured in DMEM/high glucose medium 
with 10% FBS overnight. On the second day, cells were treated with various 
concentrations of metformin in 10 ml of medium for 3 days. On the fifth day, the cells 
were treated with various concentrations of metformin in an additional 10 ml of fresh 
medium for another 3 days. All the supernatants and cells were collected, and cells 
were counted using a Z1 Coulter Particle Counter (Beckman Coulter, Brea, CA, 
USA). Triplicate samples were collected at each time point. Statistical analysis was 
done with GraphPad Prism for Windows. 
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2.11 Western Blot Analysis 
BT-474 and MDA-MB-361 cells were treated with various 
concentrations of metformin or rosiglitazone for 2 days or 6 days. Standard 
Western blotting of whole-cell lysates was performed with antibodies for 
PKM2, PDK1, PARP (Cell Signaling Technologies), and c-MYC (Epitomics). 
β-ACTIN (Sigma) was used as a control for loading and transfer. To 
determine the c-MYC proteasome-dependent degradation, BT-474 cells were 
treated with metformin for 2 days, and 10 µM of MG132 was applied 6 hours 
before sample collection. Cell lysates were subjected to standard Western 
blotting for c-MYC. For the c-Myc ubiquitination assay, BT474 cells were 
treated with MG132 for 6 hours before sample collection. Cell lysates were 
immunoprecipitated with anti-ubiquitin antibody and, polyubiquitinated c-
Myc was immunoblotted with anti-c-MYC antibody. To determine the c-
MYC turnover rate, we added 500 µg/ml cycloheximide to the culture 
medium, and collected samples at different time points. c-MYC density was 
quantified using Image J software and plotted with GraphPad Prism for 
Windows. 
 
2.12 Quantitative Real-Time Polymerase Chain Reaction 
For quantitative real-time polymerase chain reaction (qRT-PCR), total 
RNA was collected from BT-474 cells using Trizol reagents (Invitrogen), and 
cDNA was synthesized using an iScript cDNA synthesis kit (BioRad). qRT-
PCR was performed with an iQ-SYBR Green Supermix (BioRad) and an 
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iCycler CFX96 RT-PCR detection system (BioRad). Primer sequences were showed 
in Table 3. 18S rRNA was used for normalization. Statistical analysis was done with 
GraphPad Prism for Windows.  
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Table 2. Quantitative Real-Time PCR Primer List 
c-MYC-Forward 5’-GCTGTAGTAATTCCAGCGAGAGACA-3 
c-MYC-Reverse 5’-CTCTGCACACACGGCTCTTC-3’ 
PKM2-Forward 5’-CGCCCACGTGCCCCCATCATTG-3’ 
PKM2-Reverse 5’-CAGGGGCCTCCAGTCCAGCATTCC-3’ 
18S rRNA-Forward 5’-CGGCGACGACCCATTCGAAC-3’ 
18S rRNA-Reverse 5’-GAATCGAACCCTGATTCCCCGTC-3’ 
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2.13 Enzyme-linked Immunosorbent Assay 
Blood samples were taken from MMTV-ErbB2/Lepr
+/+
 mice, MMTV-
ErbB2/Lepr
db/db
 mice, MMTV-ErbB2/Lepr
db/db
 mice with metformin treatment, and 
MMTV-ErbB2/Lepr
db/db
 mice with rosiglitazone treatment. Serum samples were 
collected by using BD Microtainer tubes with ethylenediaminetetraacetic acid EDTA 
(REF# 365973) and were frozen at -80 °C. An enzyme-linked immunosorbent assay 
(ELISA) was performed according to the manufacturer’s instructions (EMD Millipore, 
rat/mouse insulin 96-well plate assay, cat# EZRMI-13K, Missouri, USA). Briefly, 
mouse serum samples were thawed on ice, and 10 µl of sample was added to the plate. 
Then, 80 µl of detection antibody was added to all wells. The plate was covered with 
plate sealer and incubated at RT for 2 hours on an orbital microtiter plate shaker. 
After the plate was washed by wash buffer, 100 µl of enzyme solution was added to 
all wells, and the plate was incubated at RT for 30 minutes on the plate shaker. After 
the plate was washed again with wash buffer, 100 µl of substrate solution was added 
to all wells, and the plate was incubated on the shaker for 20 minutes. Then, 100 µl 
stop solution was added to all wells and absorbance was measure at 450 nm and 590 
nm. Statistical analysis was done with GraphPad Prism for Windows. 
 
2.14 Multiplex Assay 
Tumor samples were isolated from MMTV-ErbB2/Lepr
db/db
 mice treated with 
metformin, rosiglitazone, or control group and stored at -80 °C. Fresh tumor lysates 
were prepared on assay day, and a multiplex assay was performed according to the 
manufacturer’s instructions (EMD Millipore, 11-Plex Akt/mTOR Panel – 
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Phosphoprotein, Cat# 48-611). Briefly, tumor lysates were diluted 1:1 with 
MILLIPLEX MAP Assay Buffer 2. Bead suspension and diluted lysates were added, 
and the assay plate was incubated overnight at 4 °C on a plate shaker protected from 
light. On the second day after the plate was washed with wash buffer, biotinylated 
reporter was added to each well, and the plate was incubated for 1 hour at RT on the 
plate shaker and protected from light. After the reporter was removed via vacuum 
filtration, MILLIPLEX MAP streptavidin-phycoerythrin was added to each well, and 
the plate was incubated for 15 minutes at RT on the plate shaker and protected from 
light. Without removing streptavidin-phycoerythrin, we added MILLIPLEX MAP 
amplification buffer to each well; the plate was incubated for 15 minutes at RT on the 
plate shaker and protected from light. Finally, the buffer was removed via vacuum 
filtration, and the beads in each well were resuspended using MILLIPLEX MAP assay 
buffer 2. The plate was read using Luminex 200, and the data were analyzed with 
GraphPad Prism for Windows. 
 
2.15 Adipokine Array Analysis 
Serum samples were prepared as previously described for the ELISA. An 
adipokine array assay was performed according to the manufacturer’s instructions 
(R&D Systems, mouse adipokine array, Cat# ARY013). Briefly, membranes were 
blocked for 1 hour on a rocking platform. Three serum samples from each group of 
mice were premixed together and a detection antibody cocktail was added to serum 
samples following 1 hour of incubation at RT. After the blocking solution was 
removed, the sample-antibody mixtures were added to the membranes, and the 
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membranes were incubated overnight at 4 °C on a rocking platform. After the 
membranes were washed with wash buffer, membranes were incubated with 
streptavidin-HRP solution for 30 minutes and subjected to X-ray film exposure. 
 
2.16 Graphs and Statistical Analysis 
The log-rank test was used to determine the statistical significance of survival 
analysis. An unpaired t-test with Welch’s correction was performed when comparing 
2 groups. One-way analysis of variance followed by Bonferroni’s multiple 
comparisons test was performed when comparing 3 or more groups. All tests were 
performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, 
LaJolla, CA, USA, www.graphpad.com). Results are expressed as means ± 95% 
confidence interval (CI). P < 0.05 was considered statistically significant. 
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CHAPTER 3. RESULTS 
 
3.1 Generating MMTV-ErbB2/Lepr
db/db
 transgenic mouse model 
Previous studies had shown that diabetes inhibits mammary gland 
development therefore inhibits tumorigenesis in transgenic mouse model 
(Cleary et al., 2004; Zheng et al., 2011). However, the tumor resistance B6 
genetic background may life span of the MMTV-drived transgenes is longer 
than the Lepr
db/db
 mice. The mice eventually died due to diabetes or obesity 
before breast cancer development. To verify previous findings, we generated 
our diabetic HER2
+ 
breast cancer mouse model as shown in Figure 3.  
 
Mice were backcrossed into an FVB genetic background, and DM2 
was validated via OGTTs (Figure 4A and 4B) and ITTs (Figure 4C and 4D). 
Compared with the blood glucose levels in the MMTV-ErbB2/Lepr
+/+ or db/+
 
mice, blood glucose remained high in the MMTV-ErbB2/Lepr
db/db
 mice, 
indicating that the latter group developed diabetes. The body weight of 
MMTV-ErbB2/Lepr
db/db
 mice was significantly greater than that of their 
control MMTV-ErbB2/Lepr
+/+
 littermates (Figure 4E).  
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Figure 4. MMTV-ErbB2; Lepr
db/db
 mice have insulin resistance and obesity 
phenotype 
A) Oral glucose tolerance test (OGTT) and C) Insulin tolerance test (ITT) were 
performed on MMTV-ErbB2/Lepr
+/+
 mice (n=6) and MMTV-ErbB2/Lepr
db/db
 mice 
(n=5). Area under the curve for B) OGTT and D) ITT were plotted to show the 
significance. Values are means ± 95% confident interval (CI). E) Mouse body weight 
change for the MMTV-ErbB2/Lepr
+/+
 mice versus MMTV-ErbB2/Lepr
db/db
 mice. 
 
E 
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3.1 Diabetes promotes breast cancer progression and reduces overall survival in 
the MMTV-ErbB2/Lepr
db/db
 transgenic mouse model 
Next, we sought to determine the impact of diabetes on breast cancer 
progression. Paired mice were dissected at the same age, and mammary glands were 
isolated and subjected to whole-mount staining. The tumor volume was significantly 
greater (P < 0.01) in the MMTV-ErbB2/Lepr
db/db
 mice than in the MMTV-
ErbB2/Lepr
+/+
 mice (Figure 5A and 5B). In addition, the MMTV-ErbB2/Lepr
db/db
 
mice died at a significantly younger age than MMTV-ErbB2/Lepr
+/+
 mice (Figure 6A, 
P = 0.0004). The median survival duration for the MMTV-ErbB2/Lepr
db/db
 and 
MMTV-ErbB2/Lepr
+/+
 mice was 5.9 months and 7.6 months, respectively. Tumor-
free survival was also dramatically shorter in the MMTV-ErbB2/Lepr
db/db
 than in the 
MMTV-ErbB2/Lepr
+/+
 mice (Figure 6B, P < 0.0001). The median tumor-free survival 
duration for the MMTV-ErbB2/Lepr
db/db
 and MMTV-ErbB2/Lepr
+/+
 mice was 5.3 
months and 6.7 months, respectively. These data indicate that DM2 group has a 
poorer outcome than the non-DM2 group in the HER2
+
 breast cancer mouse model. 
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Figure 5. DM2 promotes breast cancer progression in MMTV-ErbB2; Lepr
db/db
 
mouse model 
A) Representative mammary whole mount staining for the MMTV-ErbB2/Lepr
+/+
 
mice versus MMTV-ErbB2/Lepr
db/db
 mice. Tumor area was circled in yellow. LN= 
lymph node. B) Quantitative analysis of A). Pictures were taken under dissection 
microscope and quantified by Image-Pro software. Values are means ± 95% CI. 
Mouse number: MMTV-ErbB2/Lepr
+/+
=13; MMTV-ErbB2/Lepr
db/db
=12. 
A 
B 
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Figure 6. DM2 reduces overall survival and tumor-free survival in MMTV-
ErbB2; Lepr
db/db
 mouse model 
A) Overall survival and B) Cumulative tumor incidence for MMTV-ErbB2/Lepr
+/+
 
mice (n=16) versus MMTV-ErbB2/Lepr
db/db
 mice (n=12). The log-rank test was used 
to determine the statistical significance of survival analysis. 
A 
B 
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3.2 Anti-insulin resistance treatments attenuate tumor progression and improve 
overall survival in HER2
+
 breast cancer diabetic mouse model 
MMTV-ErbB2/Lepr
db/db
 mice were assigned to one of three groups: 
non-treatment control, metformin treatment, or rosiglitazone treatment. The 
treatments prolonged overall survival (Figure 7A) and tumor-free survival 
(Figure 7B) in the mouse model. Mammary glands were isolated from mice of 
similar ages and then subjected to whole-mount staining. Whole-mount 
staining showed that anti-insulin resistance treatments inhibited tumor 
progression in the mammary glands (Figure 8A) and significantly reduced the 
tumor size (Figure 8B, P < 0.0001). Ductal carcinoma in situ was found in the 
mammary fat pad paraffin sections from mice treated with metformin, 
indicating that metformin treatment postponed breast cancer progression in 
MMTV-ErbB2/Lepr
db/db
 mice (Figure 9). Histology analysis showed that 
tumor samples from MMTV-ErbB2/Lepr
db/db
 mice were poorly differentiated 
with solid growth patterns, high nuclear grades, and high mitotic counts. 
Compared with control samples, the anti-insulin resistance treatment groups 
were moderately differentiated with glandular formation and lower mitotic 
counts (Figure 10). Drug treatments extented overall survival, delayed tumor 
onset, and reduced cancer aggressiveness in our diabetic HER2
+
 breast cancer 
mouse model. 
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Figure 7. Anti-insulin resistance treatments improve overall survival and tumor-
free survival in MMTV-ErbB2; Lepr
db/db
 mouse model 
A) Overall survival time for MMTV-ErbB2/Lepr
db/db
 mice treated with control (n=12), 
metformin (n=13), and rosiglitazone (n=13). B) Cumulative tumor incidence rate for 
MMTV-ErbB2/Lepr
db/db
 mice in different treatment groups. The log-rank test was 
used to determine the statistical significance of survival analysis. 
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Figure 8. Anti-insulin resistance treatments attenuate tumor progression in 
MMTV-ErbB2/Lepr
db/db
 mice 
A) Representative mammary whole mount staining for the MMTV-ErbB2/Lepr
db/db
 
mice in different treatment groups. B) Quantitative bar graph represents of tumor size 
from C). Values are means ± 95% CI. Mouse number: control=12; metformin=6; 
rosiglitazone=6. 
 
 
  
A B 
 
 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Metformin treatments delays tumor progression in MMTV-
ErbB2/Lepr
db/db
 mice 
A) Mammary fat pads were collected from metformin treatment mice and H&E 
staining was performed on paraffin sections. A low power view (20X) shows two 
microscopic foci of dauctal carcinoma in situ (DCIS). B) and C) Enlarged view of 
two foci of DCIS, which shows enlarged ducts with solid proliferation of 
polymorphic tumor cells with high nuclear and cytoplasmic ratio. Arrow points 
mitotic figure. 
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Figure 10. Anti-insulin resistant treatments repress cancer progression in 
MMTV-ErbB2/Lepr
db/db
 mice. 
Tumor samples were harvested from different treatment groups and H&E staining 
was performed on paraffin sections. Pictures were taken under 40X and pathology 
analysis was done by pathologist. Arrow: mitosis. Scale bar: 100 μm. 
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3.3 Anti-insulin resistance treatments reduce the cancer metabolism in vivo 
To determine whether anti-insulin resistance treatments change the dynamics 
of the metabolic processes in MMTV-ErbB2/Lepr
db/db
 mice, we performed MRSI to 
monitor the dynamic flux of pyruvate into lactate, which is the end product of aerobic 
glycolysis and an important marker for cancer metabolism. MRI was performed 
before the substrate [1-
13
C] pyruvate injection, and the tumor area was located 
(Figure 11). By taking advantage of hyperpolarized technology, we injected the 
substrate [1-
13
C] pyruvate into MMTB-ErbB2/Lepr
db/db
 mice and traced the [1-
13
C] 
signal to lactate in vivo (Figure 12A and 12B). Metformin treatment for 2 weeks 
caused about an 80% reduction in pyruvate/lactate conversion (Figure 12A and 12C), 
and 2 days of rosiglitazone treatment showed about a 50% reduction (Figure 12B and 
12C). These data indicate that anti-insulin resistance treatments reduce 
pyruvate/lactate conversion and alter cancer metabolism in vivo. 
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Figure 11. MRI image of tumor localization in  a MMTV-ErbB2/Lepr
db/db
 mouse 
Representative T2-weighted magnetic resonance imaging (MRI) for localization of 
the tumor in a living MMTV-ErbB2/Lepr
db/db
 mouse before hyperpolarized 
13
C-
pyruvate injection. 
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Figure 12. Anti-insulin resistant treatments reduce cancer metabolism in vivo 
and in vitro 
A) Magnetic resonance spectroscopic imaging (MRSI) was performed on MMTV-
ErbB2/Lepr
db/db
 mice. Chemical shift after hyperpolarized 
13
C-pyruvate was injected 
into MMTV-ErbB2/Lepr
db/db
 mice before (left) or after (right) metformin treatment 
and B) rosiglitazone treatment. C) Quantitative bar graph represents the 
lactate/pyruvate conversion in tumor from A) and B) 
  
C 
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3.4 Metformin treatment reduces mitochondrial respiration capacity and 
glycolysis in vitro 
To further evaluate the impact of metformin treatment on cancer metabolism, 
we isolated cancer cells from the primary tumors of MMTB-ErbB2/Lepr
db/db
 mice and 
seeded them into a Seahorse microplate. OCR and ECAR were measured using the 
Seahorse instrument. OCR was significantly lower in cells treated with 300 µM 
metformin than in non-treated cells (Figure 13A), indicating that mitochondrial 
respiration capacity was altered. Decreased ECAR also indicated that lactate 
production was attenuated, which confirms that glycolysis was reduced by metformin 
treatment (Figure 13B), as we observed in the MRSI experiment in vivo. These data 
suggest that mitochondrial respiration and both anaerobic and aerobic glycolysis were 
reduced upon metformin treatment. Statistical analysis of the area under the curve for 
OCR and ECAR revealed a significant reduction after metformin treatment (Figure 
13C). 
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Figure 13. Metformin treatment reduces oxygen consumption (OCR) and extra 
cellular acidification rate (ECAR) in vitro 
A) OCR and B) ECAR were measured by Seahorse analyzer. Tumor cells were 
harvested from MMTV-ErbB2/Lepr
db/db
 mice without any treatment and seeded into 
96-well plate for Seahorse analysis. Values are means ± standard deviation. C) 
Quantitative analysis of OCAR and ECAR from A) and B). Values are means ± 95% 
CI. 
A 
C 
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3.5 Metformin treatment inhibits proliferation, induces apoptosis, and 
suppresses cancer metabolism in human HER2
+
 breast cancer cell lines 
To determine whether metformin treatment also represses cancer progression 
and cancer metabolism in human HER2
+
 breast cancer cells, we conducted the 
following experiments using BT-474 and MDA-MB-361 cells. We first split the cells 
at low density in 100 mm
2
 dishes and treated the cells with metformin at various 
concentrations for 6 days. To ensure the minimum loss of dead or detached cells, we 
applied an additional 10 ml of medium and metformin without removing any culture 
medium. All supernatant and cells were collected, and the cells were quantified via a 
Z1 Coulter Particle Counter. In fact, metformin treatment efficiently inhibited cell 
proliferation (one-way analysis of variance, P<0.001, Figure 14A and 14B) started 
from 500 µM and induced apoptosis at 2000 µM (Figure 14C). 
 
From the previous experiments (Figure 12 and 13), we learned that anti-
insulin resistance treatments reduced cancer metabolism in vivo and in vitro. We 
therefore sought to determine the target of metformin treatment in human HER2+ 
breast cancer cell lines. c-MYC is a major player in cancer metabolism by controlling 
many enzymes in the glycolysis pathway at the transcriptional level. We sought to 
determine whether metformin treatment is involved in regulating c-MYC expression. 
Indeed, Western blotting showed that c-MYC expression was suppressed by 
metformin treatment (Figure 14C).  
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Figure 14. Metformin treatment inhibits cell proliferation, increases apoptosis, 
and suppresses key metabolism regulators in Her
2+
 human breast cancer cell 
lines. 
A) BT-474 and B) MDA-MB-361 cell proliferation after 6 day metformin treatment 
at various concentrations. C) Western blot analysis of key metabolic protein 
expression and PARP cleavage after 6 days metformin treatment. 
A B 
C 
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In addition, PKM2, the key step enzyme for pyruvate/lactate conversion also 
controlled by c-MYC, was downregulated by metformin treatment (Figure 14C). 
These data provide the link between the reductions in c-MYC, PKM2, and lactate 
production that we observed in vivo (Figure 12) and in vitro (Figure 13). We also 
performed qRT-PCR in BT-474 cells to determine the mRNA expression level of c-
MYC and its downstream targets. Our data indicated that both c-MYC and PKM2 
were downregulated at the transcriptional level in the presence of 500 µM metformin 
treatment (Figure 15A). After 2 days of metformin treatment, the c-MYC protein 
level was restored to a level comparable to that of the control in the presence of 
MG132, indicating that metformin treatment has a secondary mechanism of 
proteasome-dependent degradation (Figure 15B). A band at high molecular weight 
was found in the stacking gel of the ubiquitination assay, suggesting that c-MYC was 
highly ubiquitinated and degraded upon 2 days of metformin treatment (Figure 4F). 
The c-MYC protein turnover rate was also greater than that of the control (Figure 4G). 
Collectively, our results show that metformin treatment at clinical relevant 
concentrations regulates cell metabolism by downregulating c-MYC at both 
transcriptional and post-translational levels. 
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Figure 15. Metformin treatment suppresses PKM2 gene expression through 
inhibiting c-MYC expression and promoting c-MYC degradation in Her
2+
 
human breast cancer cell lines 
A) Real-Time PCR analysis of c-MYC (left) and PKM2 (right) mRNA expression in 
BT-474 cells after 2 days metformin treatment at various concentration. B) BT-474 
cells were pretreated with metformin for 2 days and cell lysates were collected after 6 
hours MG132 treatment. c-MYC protein level were shown in western blot. C) BT474 
cells were treated with MG132 for 6 hours before harvesting. Cell lysates were 
immunoprecipitated with anti-ubiquitin antibody and polyubiquitinated c-Myc was 
immunoblotted with anti-c-MYC antibody. Arrow indicated highly ubiquitinated c-
MYC at stacking gel. D) BT-474 cells were pretreated with metformin for 2 days and 
cell lysates were collected after cycloheximide (CHX) treatment at various time 
points. Western bolt represented the c-MYC protein level. E) c-MYC protein 
turnover. Quantitative analysis for c-MYC protein from the upper panel. Density was 
set as 100% at zero time point in each group. 
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3.6 Anti-insulin resistance treatments reduce systemic insulin level, suppress 
mTOR/AKT signaling in tumor, and regulate adipokine secretion profiles 
From our aforementioned results, we learned that metformin treatment 
can efficiently suppress mitochondrial respiration, lactate production, 
proliferation and c-MYC mRNA expression in cancer cells. Next, we sought 
to evaluate the systemic impact of anti-insulin resistance treatments on our 
diabetic HER2
+
 breast cancer mouse model. Since metformin is the first-line 
treatment for DM2, we expected metformin treatment to improve insulin 
resistance in MMTV-ErbB2/Lepr
db/db
 mice (Figure 16). To further evaluate the 
systemic effect of anti-diabetic treatments in vivo, we performed a rat/mouse 
insulin ELISA assay. The level of insulin was 15-fold higher in the MMTV-
ErbB2/Lepr
db/db
 mice than in the MMTV-ErbB2/Lepr
+/+
 mice (P<0.001), and 
dramatically decreasing in metformin and rosiglitazone treatment groups 
(P<0.01, Figure 17). This microenvironment change limited the insulin supply 
to the cancer cells and suppressed the mTOR/AKT signaling pathway in 
mouse tumors as shown by p-AKT-S473 and p-RPS6-S235/S236 (Figure 18). 
 
DM2 is a severe metabolic disease and often comes with increased 
body weight and adipose tissue. Therefore, we sought to assess the adipokine 
profile changes in MMTV-ErbB2/Lepr
db/db
 mice (Figure 19A), and more 
importantly, assess the profile upon anti-insulin resistance treatments (Figure 
19B). Interestingly, we found that drug treatments reversed the impact of 
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DM2 on the expression level of Adiponectin, Fibroblast growth factor 1 (FGF1), 
Chemokine (C-C motif) ligand 2  
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Figure 16. Metformin treatment improved type 2 diabetes in MMTV-
ErbB2/Lepr
db/db
 breast cancer mouse model 
A) OGTT and B) ITT were performed on MMTV-ErbB2/Lepr
db/db
 mice (n=4) before 
and after 2 weeks metformin treatment on the same mice. Area under the curve for C) 
OGTT and D) ITT was analyzed. Paired t-test was performed to show the significant 
difference. Values are means ± 95% CI. 
  
A 
B 
C D 
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Figure 17. DM2 condition increases insulin levels and anti-insulin resistance 
treatments significantly reduce insulin levels in MMTV-ErbB2/Lepr
db/db
 breast 
cancer mouse model 
ELISA analysis for the serum insulin level was performed from different groups of 
mice. WT: MMTV-ErbB2/Lepr
+/+
 mice=10; DB: MMTV-ErbB2/Lepr
db/db
 
mice/control=12; DB/Met: MMTV-ErbB2/Lepr
db/db
 mice/metformin treatment=10; 
DB/Rosi: MMTV-ErbB2/Lepr
db/db
 mice/rosiglitazone=16. Values are means ± 95% CI. 
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Figure 18. Multiplex analysis for mTOR/Akt signaling pathway 
Tumors were harvested from MMTV-ErbB2/Lepr
db/db
 mice treated with control 
(n=24), metformin (n=6), and rosiglitazone (n=6). 
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Figure 19. Adipokine expression profile in MMTV-ErbB2/Lepr
db/db
 mice 
A) Serum adipokine levels in MMTV-ErbB2/Lepr
db/db
 mice comparing with MMTV-
ErbB2/Lepr
+/+
 mice. Serum samples from 3 mice of each group were mixed before 
incubating with adipokine array. B) Adipokine expression profile for MMTV-
ErbB2/Lepr
db/db
 mice treated with control, metformin, and rosiglitazone. 
A 
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(MCP1) and receptor of advance glycosylation end products (RAGE). These 
adipokines may associate with anti-insulin resistance treatments and contribute to the 
beneficial impact on HER2
+
 breast cancer progression. 
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CHAPTER 4. DISSCUSSION 
 
Our findings suggest that DM2 promotes the progression of HER2
+
 breast 
cancer, and this aggressiveness is attenuated by anti-insulin resistance treatments. We 
also successfully established a transgenic animal model and confirmed that the 
survival duration of mice with DM2 and HER2
+
 breast cancer was shorter than that of 
control mice. Furthermore, by administrating anti-insulin resistance treatments to the 
diabetic HER2
+
 breast cancer model, we demonstrated that metformin and 
rosiglitazone treatments significantly prolong overall survival and alter the metabolic 
status. All these results indicate the potential application of anti-insulin resistance 
treatments in HER2
+ 
breast cancer patients with DM2. 
 
4.1 A successful DM2 HER2
+
 breast cancer transgenic mouse model 
Lepr
db/db
 mice were discovered more than 40 years ago as an animal model in 
DM2 research (Belke and Severson, 2012; Hummel et al., 1966). Previous studies 
indicated that the Lepr
db/db
 mouse model has deficient mammary gland development 
on a C57BL/6 genetic background. Cleary et al. (Cleary et al., 2004) and Zheng et al. 
(Zheng et al., 2011) also tried to cross MMTV-TGF-α mice or MMTV-Wnt-1 mice 
with Lepr
db/+
 mice and maintain the mice on a C57BL/6 genetic background. They 
claimed that the leptin receptor deficiency suppressed the development of mammary 
tumors. However, the life expectancy of the MMTV-TGF-α mice or MMTV-Wnt-1 
mice is longer than that of Lepr
db/db
 mice, and the C57BL/6 genetic background is 
actually resistant to tumor progression in mouse models. In our study, we crossed our 
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transgenic mouse model in a tumor-prone FVB genetic background instead of 
a tumor-resistant C57BL/6 genetic background and found that DM2 promotes 
HER2
+
 breast cancer progression. To our knowledge, we are the first group to 
successfully generate hyperinsulinemic, hyperglycemic, and obese MMTV-
ErbB2/Lepr
db/db
 mice. Therefore, we could use this animal model to assess the 
therapeutic effect of anti-insulin resistance agents. 
 
4.2 Demonstrating the anti-cancer effect of anti-insulin resistance treatments by 
using clinical relevant concentration 
Metformin is the most frequently prescribed anti-insulin resistance 
drug for DM2 patients, and many studies have shown that both metformin and 
rosiglitazone have anticancer activity. Studies showed that treatment with 
metformin and/or rosiglitazone inhibited cancer cell proliferation (Feng et al., 
2011; Zhuang and Miskimins, 2008), induced cell apoptosis (Feng et al., 
2011), selectively reduced cancer stem cell populations in vitro (Hirsch et al., 
2013; Hirsch et al., 2009), and attenuated cancer cell growth in vivo 
(Anisimov et al., 2005a; Anisimov et al., 2005b; Fierz et al., 2013). However, 
none of these studies revealed alterations in breast cancer metabolism in vivo, 
and the majority studies of anti-insulin resistance treatments used either a 
high-fat diet or drugs to induce diabetes or the engraftment of tumor cells in 
the mice, which does not represent the true circumstances of cancer 
progression in the presence of DM2 in a transgenic setting. Moreover, the 
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majority of the studies were conducted by using metformin and/or rosiglitazone at 
concentrations that were not clinically relevant.  
 
Other studies did not test these agents in an obese DM2 mouse model. 
Anisimov et al. showed the impact of metformin on tumor progression and survival in 
non-diabetic MMTV-ErbB2 mice (Anisimov et al., 2005a). Similarly, Fierz et al. 
established the effects of anti-diabetic drugs in a nonobese DM2 mouse model (Fierz 
et al., 2013). We sought to assess the effects of anti-insulin resistance treatments in 
the setting of HER2
+
 breast cancer, DM2, and obesity. Therefore, we treated our 
MMTV-ErbB2/Lepr
db/db
 mice with metformin or rosiglitazone at a clinical relevant 
concentration before palpable tumor formation and observed that tumor progression 
was significantly reduced and survival time was prolonged. In addition, the drugs did 
not inhibit tumor progression once the tumor had been established, indicating that the 
anti-diabetic drugs work better as cancer prevention agents (data not shown). 
 
4.3 Real-time observation of anti-insulin resistance treatments alter breast 
cancer metabolism by directly inhibiting oxidative phosphorylation and 
glycolysis in vitro and in vivo 
By assessing our MMTV-ErbB2/Lepr
db/db
 mice with MRSI, we found that 
metformin or rosiglitazone treatments reduced cancer metabolism in the living mice. 
For this particular method, we monitored the glycolysis real-time in vivo. 
Interestingly, the rate at which 
13
C-pyruvate was converted to 
13
C-lactate was reduced 
significantly after 2 days of rosiglitazone treatment (Figure 12B), but not after 2 days 
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of metformin treatment (data not shown). The reduction in pyruvate/lactate 
conversion was found in the group treated with metformin for 2 weeks (Figure 
12A), indicating that the physiologically relevant concentration of oral 
metformin may affect cancer metabolism only in a long-term treatment 
regimen. These results suggest that metformin and rosiglitazone regulate 
cancer metabolism via different mechanisms that need to be investigated. 
 
Warburg effect is an important factor in cell metabolism (Vander 
Heiden et al., 2009; Warburg, 1956) and one of the hallmarks of cancer 
(Hanahan and Weinberg, 2011; Yeung et al., 2008). Regardless of whether 
oxygen is present, cancer cells tend to undergo aerobic glycolysis and convert 
most glucose to lactate instead of moving into TCA cycle. To confirm our 
observation in vivo, we isolated cancer cells from the primary tumor sites of 
MMTV-ErbB2/Lepr
db/db
 mice and monitored the impact of metformin 
treatment directly on cancer cells. As a well-known mitochondrial complex I 
inhibitor (Owen et al., 2000), metformin at a clinically relevant concentration 
efficiently suppressed oxygen consumption, indicating that the mitochondrial 
respiratory chain reaction was repressed (Figure 13A). Although a previous 
study indicated that glycolysis increases when mitochondrial complex I is 
inhibited owing to the glycolysis flux (Brunmair et al., 2004), we observed 
that lactate production was decreased upon treatment with 300 µM metformin 
(Figure 13B), which is consistent with the MRSI finding. This result 
demonstrated that metformin may also affect multiple key components in the 
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glycolysis pathway, of which c-MYC is a primary regulator (Miller et al., 2012). 
 
4.4 Metformin treatment inhibits c-MYC mRNA expression and induces c-MYC 
proteasome degradation 
To expend our study closer to human, we selected two human HER2
+
 breast 
cancer cell lines for our in vitro experiments. The proliferation of both BT-474 and 
MDA-MB-361 cells was inhibited at a clinically relevant concentration of metformin 
treatment (Figure 14A and 14B). However, metformin treatment induced apoptosis at 
a higher dose that was not a clinically relevant concentration (Figure 14C). c-MYC 
protein level was indeed decreasing upon metformin treatment. Additionally, the c-
MYC downstream target PKM2, which is important for switching the metabolism to 
aerobic glycolysis (Christofk et al., 2008) was also repressed (Figure 14C and 15A). 
These findings may explain why there was no increase of lactate production when 
oxidative phosphorylation was inhibited. At the end, the glycolysis flux may have 
been blocked, and the metabolites may have been converted to phosphoenolpyruvate 
(PEP), 2-phosphoglycerate and 3-phosphoglycerate (2- and 3-PGA) as previous 
described (Owen et al., 2000). These intermediate metabolites are precursors for the 
pentose phosphate pathway (PPP) to synthesis nucleotides as building blocks for 
cancer cells. These accumulated intermediated metabolites also explain why 
metformin treatment can only postpone cancer progression but cannot eradicate it. 
 
We next sought to determine the extent to which c-MYC is reduced at the 
transcriptional and/or post-translational level. Upon 500μM metformin treatment, 
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there was a significant difference at the c-MYC mRNA level (Figure 15A), 
suggesting that metformin may modulate c-MYC in a DICER-microRNA-33-
c-MYC cascade according to previous findings (Blandino et al., 2012). In 
addition, c-MYC protein was restored to a comparable level in the presence of 
MG132, suggesting that metformin treatment was involved in c-MYC 
degradation (Figure 15B). For the ubiquitination assay, the endogenous c-
MYC ubiquitination was first detected via immunoprecipitation with anti-
ubiquitin antibody and then immunoblotted with anti-c-MYC antibody in BT-
474 cells. The stacking gel was intentionally preserved, and Western blotting 
was performed for the whole gel. A highly ubiquitinated c-MYC was found in 
the stacking gel, and metformin treatment induced ubiquitination starting at 
500 µM (Figure 15C). Although high concentrations of metformin treatment 
did not cause c-MYC ubiquitination in a dose-dependent manner in BT-474 
cells, the clinically irrelevant concentrations may already disrupt and affect 
normal protein production in the cells. The c-MYC turnover rate was faster in 
the presence of 500 µM metformin (Figure 15D and E), supporting the notion 
that metformin treatment promotes c-MYC protein degradation. 
 
4.5 Systematic effect of anti-insulin resistance treatments on breast cancer and 
microenvironment 
Besides the impact of anti-insulin resistance treatments in cancer, we 
evaluated the systemic effects of the anti-insulin resistance treatments and the 
potential crosstalk between cancer cells and the microenvironment in our 
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diabetic HER2
+
 mouse model. The serum insulin level (Figure 17) was reduced, and 
insulin resistance was improved in MMTV-ErbB2/Lepr
db/db
 mice (Figure S3) after 
anti-insulin resistance treatments. Although the downstream targets of insulin 
receptor signaling pathway and HER2 signaling pathway are overlap, anti-insulin 
resistance treatments prevented further stimulation from insulin and attenuated the 
mTOR/AKT signaling pathway (Figure 18), thereby gradually preventing cancer 
progression. In addition, by analyzing the adipokine profile, we identified the 
adipokines that were up-regulated under diabetic conditions (Figure 19A) and found 
adiponectin, FGF-1, MCP-1, and RAGE were significantly down-regulated by anti-
insulin resistance treatments (Figure 19B). These four adipokines may serve as anti-
cancer regulators in HER2
+
 breast cancer progression. This finding supports the idea 
that anti-insulin resistance treatments at clinically relevant concentration not only 
altered cancer cell metabolism but also rendered the microenvironment unfavorable to 
tumor progression in our diabetic HER2
+
 breast cancer mouse model. 
 
In conclusion, we established a new animal model to assess the impact of 
DM2 on breast cancer progression and showed that anti-insulin resistance treatments 
may delay tumor onset and retard cancer progression in MMTV-ErbB2/Lepr
db/db
 mice. 
The treatments not only stopped proliferation and altered metabolism in cancer cells 
but also changed the microenvironment through systemic regulation of insulin levels 
and adipokine expression. To take bench research to the bedside, these results suggest 
that anti-diabetic drugs may be used as cancer prevention agents for diabetic patients 
who have increased risk of HER2
+
 breast cancer. 
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4.6 Future direction 
It had been shown that metformin and rosiglitazone react through 
distinct pathway (Fryer et al., 2002). Our data 
13
C-pyruvate data showed that 
metformin required longer treatment (2 weeks) to be able to reduced 
lactate/pyruvate conversion, while rosiglitazone only needed 2 days to achieve 
the inhibition. In addition, metformin treatment also inhibited alanine to 
pyruvate conversion (5.99%) while rosiglitazone actually increased it 
(175.68%) (data not shown). These data suggest that metformin not only 
inhibits glycolysis, it may also inhibit amino acids synthesis as building 
blocks for cancer cells. If metformin treatment is able to inhibit oxidative 
phosphorylation, aerobic glycolysis, and amino acid synthesis at the same 
time, where the glucose metabolites go? Previous study showed that an 
intermediate of the de novo purine nucleotide synthesis pathway, SAICAR 
(succinylaminoimidazolecarboxamide ribose-5’-phosphate), was involved in 
regulating PKM2 and was able to promote cancer cell survival (Keller et al., 
2012). To find the metabolites that potentially keep cancer cell survive may be 
the key to cure breast cancer. 
 
In our study, we found that metformin treatment induces c-MYC 
proteasome degradation. However, what mechanism and which E3 ligase is 
involved needs to be clarified. I previously identified that Pin1 
phosphorylation at serine 71 is necessary to form the 14-3-3σ-pin1-MYC 
complex and mediated c-MYC degradation. It will be interesting to see 
 
 
68 
 
whether metformin treatment increases Pin1 or 14-3-3σ protein levels or stimulates 
PIN1 S71 phosphorylation. 
 
We identified FGF1, MCP1 and RAGE could be the potential anti-cancer 
adipokines as therapeutic options for drug development. For example, MCP1 is a 
monocyte chemoattractant protein which may involve in the monocyte infiltration as 
cancer progress. Since metformin and rosiglitazone can inhibit the inflammatory 
response (Hirsch et al., 2013; Yki-Jarvinen, 2004), it is very interesting to know how 
anti-insulin resistance treatments can inhibit MCP1 secretion. I previously tried to 
link the reduction of MCP1 by using cancer cells as the model but failed. However, 
the MCP1 reduction could be the effect of drug treatments on microenvironment. 
Therefore, the direction should focus on adipocytes or stromal cells instead of cancer 
cells. In conclusion, solving these underlying questions may lead us to find new 
therapeutic targets for breast cancer. 
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